Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
8.63
+0.23 (2.80%)
At close: Oct 7, 2026, 4:00 PM EDT
8.63
+0.01 (0.06%)
After-hours: Oct 7, 2026, 6:01 PM EDT
Akari Therapeutics, Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Akari Therapeutics, stock has a consensus rating of "Strong Buy" and an average price target of $25.5. The average 1-year stock price forecast is 195.65% higher than the current stock price, while the lowest is $19.5 (+126.09%) and the highest is $30 (+247.83%).
Price Target: $25.5 (+195.65%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Akari Therapeutics, stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 2 |
| Buy | 1 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $27 | Buy | Reiterates | $27 | +213.04% | Oct 1, 2026 |
| Alliance Global Partners | Alliance Global Partners | Buy Reiterates $7 → $20 | Buy | Reiterates | $7 → $20 | +126.09% | Sep 16, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $30 | Buy | Maintains | $30 | +247.83% | Aug 19, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-9.05
from -0.01
EPS Next Year
-8.65
from -9.05
EPS and Forward PE are based on non-GAAP adjusted numbers.